As a part of the partnership, Health2Sync will present affected person administration software program for healthcare professionals and a cellular app for sufferers in 300 Sanofi-contracted clinics and hospitals, to appreciate an built-in and digitized diabetes administration.
The final word objective is to enhance sufferers’ understanding of insulin, enhance glucose management and lift the insulinization charge in Taiwan. Health2Sync’s analytics platform will help docs in real-time with determination making, remedy planning, and producing insights primarily based on the well being knowledge collected with affected person consent. The answer will assist determine sufferers suited to insulin initiation and facilitate insulin titration for healthcare suppliers.
WHY IT MATTERS
In line with an evaluation in 2019 Diabetes Atlas: achievements and challenges in diabetes care in Taiwan, revealed by the Taiwan Affiliation of Diabetes Educators, over 60% of diabetes sufferers in Taiwan can not attain HbA1c <7%, and the insulinization charge in Taiwan is 12%, which is comparatively low in contrast with America and European nations.
There are at present greater than 2.2 million diabetes sufferers in Taiwan, which ends up in an enormous and expensive burden on the healthcare system. Given the COVID-19 pandemic, many sufferers are hesitant to hunt the mandatory care. Thus, the flexibility to leverage digital instruments to assist healthcare professionals present a greater long-term care and administration to sufferers opened up a chance for collaboration between Sanofi and Health2Sync.
THE LARGER TREND
In September 2019, Health2Sync and Fitbit partnered to help diabetes administration in Taiwan and Japan, MobiHealthNews reported. Final March, the Taiwan-based startup additionally partnered with Novo Nordisk Pharma Ltd. in Japan to help digital diabetes administration and facilitate communication between diabetics and healthcare suppliers.
ON THE RECORD
“Health2Sync’s resolution brings a brand new definition to the continual illness care loop, because of seamless knowledge assortment, real-time analytics, and in the end, well timed medical intervention. With our concentrate on digital therapeutics, there couldn’t have been a greater market than Taiwan as a begin, because of the native initiatives and strong medical follow. Our dedication to each empower sufferers and reduce the burden of the price of issues arising from diabetes will likely be additional exemplified on this partnership,” stated Ed Deng, Co-founder & CEO of Health2Sync.
“Sanofi isn’t just a pharma firm that gives drugs. Sanofi is a healthcare firm that mixes drugs and built-in care options to optimize the affected person journey. The collaboration is only a starting, and Sanofi goals to maintain bringing digital therapeutics options to achieve a complete Diabetes Digital Healthcare Ecosystem,” added Shelley Chan, Head of Diabetes, Hong Kong & Taiwan at Sanofi.